Abstract
result of radiofrequency ablation (RFA) immediately followed by breastconserving surgery (BCS) in 30 patients with T1N0 BC (Breast, 2009). Complete pathological ablation was found in 26 patients (87%) from the pathological diagnosis of tumor specimens stained with hematoxylineeosin and nicotinamide adenine dinucleotide diaphorase. Thus, we conducted a phase II study to evaluate the safety and reliability of RFA alone in BC. Material and methods: T1 and sentinel node-negative BC patients were eligible. BC with diffuse calcification or extensive intraductal component (EIC) was excluded. RFAwas performed using a LeVeen needle electrode system (Boston Scientific Corporation, USA). Primary endpoint was breast deformity after RFA, which was evaluated by calculating absolute difference of measurement from nipple to several points of the breast. Results: Twenty patients were enrolled from Apr. 2009 to Feb. 2013. There were no adverse events like skin burn, bleeding and infection. As of Jan. 2014, all patients were free of recurrence at the median follow-up of 34 months. Breast deformity after RFA was very limited in most patients. Conclusion: RFA is a promising alternative to BCS in stage I BC without EIC. No conflict of interest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have